These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

682 related articles for article (PubMed ID: 30518830)

  • 1. Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators.
    Piccinin E; Villani G; Moschetta A
    Nat Rev Gastroenterol Hepatol; 2019 Mar; 16(3):160-174. PubMed ID: 30518830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma.
    Kutlu O; Kaleli HN; Ozer E
    Can J Gastroenterol Hepatol; 2018; 2018():8543763. PubMed ID: 30228976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
    Qiu YY; Zhang J; Zeng FY; Zhu YZ
    Pharmacol Res; 2023 Jun; 192():106786. PubMed ID: 37146924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease.
    Zhang H; Léveillé M; Courty E; Gunes A; N Nguyen B; Estall JL
    Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E863-E876. PubMed ID: 32924526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Chow MD; Lee YH; Guo GL
    Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
    Serviddio G; Bellanti F; Vendemiale G
    Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer.
    Yang H; Deng Q; Ni T; Liu Y; Lu L; Dai H; Wang H; Yang W
    Int J Biol Sci; 2021; 17(15):4207-4222. PubMed ID: 34803493
    [No Abstract]   [Full Text] [Related]  

  • 10. NASH, Fibrosis and Hepatocellular Carcinoma: Lipid Synthesis and Glutamine/Acetate Signaling.
    Sunami Y
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32947972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC.
    Zhang Y; Wang H; Xiao H
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34065108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into the Role of PPARβ/δ in NAFLD.
    Chen J; Montagner A; Tan NS; Wahli W
    Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29954129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.
    Jiang CM; Pu CW; Hou YH; Chen Z; Alanazy M; Hebbard L
    World J Gastroenterol; 2014 Nov; 20(44):16464-73. PubMed ID: 25469014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover.
    Simon J; Ouro A; Ala-Ibanibo L; Presa N; Delgado TC; Martínez-Chantar ML
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
    Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP
    Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma.
    Kumar DP; Santhekadur PK; Seneshaw M; Mirshahi F; Uram-Tuculescu C; Sanyal AJ
    Hepatology; 2019 Apr; 69(4):1520-1534. PubMed ID: 30394550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of MicroRNAs in the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
    Zhang C; Wang P; Li Y; Huang C; Ni W; Chen Y; Shi J; Chen G; Hu X; Ye M; Duan S; Wang K
    Anat Rec (Hoboken); 2019 Feb; 302(2):193-200. PubMed ID: 30312023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
    Charrez B; Qiao L; Hebbard L
    World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pattern recognition receptors in the development of nonalcoholic fatty liver disease and progression to hepatocellular carcinoma: An emerging therapeutic strategy.
    Huang C; Zhou Y; Cheng J; Guo X; Shou D; Quan Y; Chen H; Chen H; Zhou Y
    Front Endocrinol (Lausanne); 2023; 14():1145392. PubMed ID: 37020586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXK1 promotes nonalcoholic fatty liver disease by mediating mTORC1-dependent inhibition of hepatic fatty acid oxidation.
    Fujinuma S; Nakatsumi H; Shimizu H; Sugiyama S; Harada A; Goya T; Tanaka M; Kohjima M; Takahashi M; Izumi Y; Yagi M; Kang D; Kaneko M; Shigeta M; Bamba T; Ohkawa Y; Nakayama KI
    Cell Rep; 2023 May; 42(5):112530. PubMed ID: 37209098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.